Association of Plasma C1q/TNF-Related Protein 3 (CTRP3) in Patients with Atrial Fibrillation

Table 1

Clinical and biochemical characteristics of AF patients and controls.

	AF patients ()	The controls ()	value
Age (years)			0.011
Male (%)	42 (56.0)	27 (57.4)	0.875
BMI (kg/m^2)			0.098
SBP (mmHg)			0.496
DBP (mmHg)			0.207
Smoking (%)			0.624
HT history (%)	44 (58.7)	32 (68.1)	0.296
HLP history (%)	41 (54.7)	33 (70.2)	0.087
DM history (%)	13 (17.3)	14 (29.8)	0.107
CHD history (%)	14 (18.9)	11 (23.4)	0.553
Anticoagulant (%)	21 (28.0)	0 (0)	<0.001
Antiplatelet drugs (%)	15 (20.0)	12 (25.5)	0.474
Statin (%)	23 (30.7)	16 (34.0)	0.697
ACEI/ARB (%)	16 (21.3)	17 (36.2)	0.073
CCB (%)	25 (33.3)	18 (38.3)	0.576
Β blockers (%)	31 (41.3)	12 (25.5)	0.075
HbAlc (%)			0.198
Cr (μmol/l)			0.798
TC (mmol/l)			0.920
TG (mmol/l)			0.124
LDL-C (mmol/l)			0.878
HDL-C (mmol/l)			0.119
Us-CRP (mg/l)	0.76 (0.04, 23.98)	1.1 (0.10, 20.64)	0.131
NT-proBNP (pg/ml)	219.90 (16.86, 3584.00)	61.52 (6.43, 1046.00)	<0.001
LAD (mm)			0.041
LAA (cm^2)			<0.001
LAP (mmHg)			0.122
LVEF (%)			0.009

NT-pro BNP and Us-CRP were presented as median (interquartile range); other characteristics were presented as . The difference in gender and smoking was analyzed by chi-square tests; AF: atrial fibrillation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HT: hypertension; HLP: hyperlipidemia; DM: diabetes mellitus; CHD: coronary heart disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; HbAlc: hemoglobin A1c; Cr: creatinine; TC: total cholesterol; TG: triglycerides; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Us-CRP: ultrasensitive C-reaction protein; NT-proBNP: N-Terminal probrain natriuretic peptide; LAD: left atrial diameter; LAA: left atrial area; LAP: left atrial pressure; LVEF: left ventricular ejection fraction. .